A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Seagen Inc.
Neonc Technologies, Inc.
Merck Sharp & Dohme LLC
Adlai Nortye Biopharma Co., Ltd.
Taiho Pharmaceutical Co., Ltd.
Apexigen America, Inc.